Table 2.
Overview of TEAEs
| Group 1 (n = 45) |
Group 2 (n = 41) |
Overall (n = 86) |
||||
|---|---|---|---|---|---|---|
| n (%) | e | n (%) | e | n (%) | e | |
| TEAEs | 37 (82.2) | 200 | 35 (85.4) | 244 | 72 (83.7) | 444 |
| TEAEs related to AIT | 27 (60.0) | 129 | 20 (48.8) | 132 | 47 (54.7) | 261 |
| Local reactions | 26 (57.8) | 110 | 20 (48.8) | 123 | 46 (53.5) | 233 |
| Systemic allergic reactions | 4 (8.9) | 14 | 1 (2.4) | 1 | 5 (5.8) | 15 |
| Other type of events | 3 (6.7) | 5 | 3 (7.3) | 8 | 6 (7.0) | 13 |
| TEAEs leading to discontinuation | 2 (4.4) | 2 | 0 | 0 | 2 (2.3) | 2 |
| Treatment-emergent SAE | 1 (2.2) | 2 | 0 | 0 | 1 (1.2) | 2 |
| Treatment-emergent SAE related to AIT | 1 (2.2) | 2 | 0 | 0 | 1 (1.2) | 2 |
n (%) refers to patients who experienced at least 1 TEAE. e, number of events (TEAEs); AIT, allergen immunotherapy; SAE, serious adverse event; TEAE, treatment-emergent adverse event.